Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Scientists may be overestimating the amount of microplastics in the environment – and the culprit is lab gloves - 2Extreme Manual for Picking a Camper Van
- 3‘Harry Potter and the Philosopher’s Stone’ trailer is raising eyebrows among Potterheads: ‘Where’s the whimsical color?’
- 4Artemis 2 astronauts fly around the moon in record-breaking lunar loop by NASA
- 5Instructions to Investigate Different Open Record Extra Offers Actually
- Indian Health Service is digging out of decades-old construction backlog for medical buildings
- What to watch for as NASA’s historic Artemis II crew prepares to lift off toward the moon
- Partake in the Outside: Senior-Accommodating Exercises for 2024
- Help Your Business with Master Web based Promoting Arrangements
- 6 Solid Vehicle Fix Administrations to Keep Your Vehicle in Prime Condition
- 2024 Manual for Light Extravagance Room Feel: What's Moving
- The 15 Most Rousing TED Chats on Self-awareness
- Find the Keys to Fruitful Venture The board: Conveying Results on Time
- ‘Democratizing space’ is more than just adding new players – it comes with questions around sustainability and sovereignty
